Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 67, Issue 1, 2008, Pages 98-104

  Vonk, Madelon C ^a   Marjanovic, Z ^b   Van Den Hoogen, F H J ^a   Zohar, S ^c   Schattenberg, A V M B ^a   Fibbe, W E ^d   Larghero, J ^c   Gluckman, E ^c   Van Laar, J M ^d   Farge, Dominique ^c   Preijers, F W M B ^a   Van Dijk, A P J ^a   Bax, J J ^d   Roblot, P ^e   Van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔTEL DIEU   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; LIFE EXPECTANCY; LONG TERM CARE; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; SURVIVAL; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MORBIDITY; MYELOABLATIVE AGONISTS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 37749001089     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.071464     Document Type: Article

References (11)

1. Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997;24:53-7.
2. Medsger TA, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Arthritis Rheum 1971;14:174.
3. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis) - classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
4. Varga J, Korn JH. Pathogenesis, emphasis on human data. In Clements PJ, Furst DE, eds. Systemic sclerosis. 2nd edn. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2004;63-98.
5. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma - development of a simple model using three disease factors at first visit. Arthritis Rheum 1999;42:2660-5.
6. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
7. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
8. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37:750-5.
9. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatol 2003;42:71-5.
10. Clements PJ. Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 1995;7:517-21.
11. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.